🎉 Celebrating our Amazing Women in Ageing Research! 🎉
Meet Maria, Postdoc in the Matic Lab 👩🔬 Maria studies how our cells respond to damage in their DNA — the instruction manual of life. 🧬
@mariapalumbieri.bsky.social
@maticlab.bsky.social
We are interested in ADP-ribosylation, PARP1 signalling, proteomics, histone PTMs, protein engineering, the DNA damage response and aging Max Planck Institute for Biology of Ageing, Cologne, Germany
🎉 Celebrating our Amazing Women in Ageing Research! 🎉
Meet Maria, Postdoc in the Matic Lab 👩🔬 Maria studies how our cells respond to damage in their DNA — the instruction manual of life. 🧬
@mariapalumbieri.bsky.social
We were delighted to have Nobel laureate Venki Ramakrishnan with us to discuss his exciting new book, "Why We Die." Thanks so much, Venki, for your fascinating and thought-provoking talk - it was truly a pleasure to have you join us!
07.10.2025 14:09 — 👍 9 🔁 1 💬 0 📌 0Apply now for a fully funded #PhD position at the Cologne Graduate School of Ageing Research and become part of our vibrant #AgingResearch commmuny.
🗓️ Deadline: November 3, 2025.
ℹ️ More info: www.ageing-grad-school.de
📣 Spread the news!
Superb News&Views on our recent paper reporting identification of ADP-ribosyl-linked serine ubiquitylation
www.nature.com/articles/s41...
• Together with a series of papers and preprints published this year, it establishes RNF114 as a reader of ADPrUb
11.07.2025 19:52 — 👍 1 🔁 0 💬 0 📌 0• Observation that serine mono-ADPrUb increases in ARH3 KO cells, raising the intriguing question of its potential role in ARH3 mutation–associated neurodegeneration
11.07.2025 19:52 — 👍 2 🔁 0 💬 0 📌 0• First reagent specific for ADPrUb, enabling both immunoblotting and immunoprecipitation
11.07.2025 19:52 — 👍 0 🔁 0 💬 0 📌 0• First mass spectrometric evidence of ADPrUb, regardless of the target residue
11.07.2025 19:52 — 👍 1 🔁 0 💬 0 📌 0• Serine mono-ADPrUb as a new type of DNA damage-induced histone modification
11.07.2025 19:52 — 👍 0 🔁 0 💬 0 📌 0• First evidence that, in cells, serine mono-ADPr by the PARP1/HPF1 writer complex is targeted by this unconventional ubiquitylation
11.07.2025 19:51 — 👍 0 🔁 0 💬 0 📌 0At its core, it’s a technological paper—necessary to overcome some of the many challenges of working with ADPrUb. But beyond the technical details, below are the main highlights:
11.07.2025 19:51 — 👍 4 🔁 1 💬 6 📌 0RNF114 is an E3 ligase that can recognize ADP-ribose (ADPr) and ubiquitin with separate domains. A proteomics approach is developed using these domains to map ADP-ribosyl-ubiquitylation sites
www.nature.com/articles/s41...
Thrilled to share my first first-author postdoc publication — a team effort with @aklvnbch.bsky.social. We present the first MS-based evidence of ADP-ribosylation–linked ubiquitin (ADPrUb) in cells after DNA damage.
Grateful for all I’ve learned and looking forward to uncovering more about ADPrUb
Really happy that our paper is finally released. We show that PARP1 and histones are targets of ADP-ribosyl-linked ubiquitylation during DNA damage and describe how to detect the dual modification. Great teamwork with @mariapalumbieri.bsky.social & thanks to everyone involved @maticlab.bsky.social !
09.07.2025 14:17 — 👍 6 🔁 2 💬 1 📌 0Our latest study on ADP-ribosyl-linked serine ubiquitylation in the context of PARP1 signaling and the DNA damage response is out today in Nature Chemical Biology www.nature.com/articles/s41...
09.07.2025 12:00 — 👍 28 🔁 10 💬 1 📌 4Huge Congratulations to Edoardo José Longarini on receiving the prestigious Peter Hans Hofschneider Prize! 🎉
www.age.mpg.de/424030/Edoar...
🎥We're excited to share the new film about our graduate programme. Get a glimpse of our faculty & PhD students and explore your research opportunities. Join us as we dive into the world of ageing research and discover what makes the CGA truly unique.👩🔬🧑🎓 www.ageing-grad-school.de/about-us/cal...
20.03.2025 15:49 — 👍 13 🔁 6 💬 0 📌 1New Paper💡PARP enzymes regulate ADP-ribosylation, a protein modification linked to cancer, infections & neurodegeneration. But it comes with two forms—MARylation (single) & PARylation (multiple). Meet dELTA-MS, a mass spec method that identifies both in one experiment!
pubs.acs.org/doi/full/10....
I'm super excited to share our study in collaboration with @jnpruneda.bsky.social, published today in @embojournal.org! We show that PARPs are modified with a non-canonical ester-linked mono-ADP-ribosylated ubiquitin species for the first time in cells: www.embopress.org/doi/full/10....
25.02.2025 17:52 — 👍 50 🔁 20 💬 4 📌 2These new antibody development efforts align with our vision that the fundamental discovery of Serine ADP-ribosylation can be converted into a technology that transforms the study of ADP-ribosylation and related PTMs.
09.02.2025 10:18 — 👍 0 🔁 0 💬 0 📌 0This preprint is part of a larger manuscript on additional antibodies and their applications to biological questions. The goal of this preprint is to share these poly-ADPr with the community without delay, as we believe they wil benefit many laboratories.
09.02.2025 10:06 — 👍 1 🔁 0 💬 0 📌 0As with our other tools, the AbD64138 clone should become widely accessible in a few months. For those familiar with our popular AbD43647 antibody, the new AbD64138 clone provides similar advantages for poly-ADPr as AbD43647 does for mono-ADPr.
09.02.2025 10:01 — 👍 0 🔁 0 💬 0 📌 0We’re particularly excited to share with the community the exceptionally high sensitivity we’ve achieved for poly-ADPr immunoblotting, all while using a faster and simpler protocol enabled by a sophisticated SpyTag-HRP format that eliminates the need for secondary antibodies.
09.02.2025 09:54 — 👍 0 🔁 0 💬 0 📌 0We’ve uploaded a bioRxiv preprint on new antibodies specific for poly-ADP-ribosylation (PARylation). These modular tools were developed and validated through novel applications of our Serine ADP-ribosylation-based technology. www.biorxiv.org/content/10.1...
09.02.2025 09:52 — 👍 5 🔁 4 💬 4 📌 0Hi everyone! The Matić Lab is now on Bluesky. Looking forward to sharing our discoveries and technologies and interacting with all of you.
29.01.2025 16:07 — 👍 4 🔁 0 💬 0 📌 0